Articles tagged "Cytomeglovirus"

2019 American Transplant Congress
CMV-Specific Cell-Mediated Immunity Early after Transplantation Discriminates R+ Transplant Patients at Risk of CMV Infection among Different Solid Organ Transplants
M. Jarque¹, A. Cachero², E. Garcia-Romero³, L. Lladó², C. Baliellas², C. Diez³, E. Melilli⁴, J. Fabregat², J. Gonzalez-Costello³, O. Bestard⁴
¹Experimentall Nephrology laboratory, IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain, ²Liver Transplant Department, Bellvitge University Hospital, L'Hospitalet de Llobregat. Barcelona, Spain, ³Heart Transplant Unit, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat. Barcelona, Spain, ⁴Kidney Transplantation Unit, Bellvitge University Hospital- IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain
*Purpose: While monitoring CMV-specific cell-mediated immunity(CMI) has shown to be effective in predicting the risk of CMV infection, comparisons across different solid organ transplants(SOT) and…
2019 American Transplant Congress
Anti-cmv Antibody (cmv-ab) And Cmv-specific Cytotoxic T Cell (cmv-tc) Positivity Are Essential To Control Severe Viremia In Seronegative (sero[-]) Pediatric Kidney Transplant Recipients (ped Ktx Pts).
B. Shin, H. Pizzo, D. Puliyanda, A. Petrosyan, D. Lovato, S. C. Jordan, M. Toyoda
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: CMV infection represents a significant morbidity factor in KTx Pts, especially CMV sero(-) Ped Pts as infections tend to be more severe and recurrent.…
2019 American Transplant Congress
Letermovir For The Treatment And Secondary Prophylaxis Of Drug Resistant CMV In Solid Organ Transplant Recipients
M. R. Pereira¹, J. G. Aaron¹, C. J. Kubin²
¹Medicine - Infectious Diseases, Columbia University Medical Center, New York, NY, ²Medicine - Infectious Diseases, NewYork Presbyterian Hospital, New York, NY
*Purpose: Although only approved for primary prophylaxis of CMV among allogeneic stem cell transplant recipients, there is great interest in the use of letermovir (LET)…
2019 American Transplant Congress
Impact of HLA Mismatches and Cytomegalovirus Seropositivity on Outcomes Following Heart Transplantation
A. Singhvi, R. Araujo-Gutierrez, M. H. Park, A. Bhimaraj, B. H. Trachtenberg, I. Hussain, A. Guha
Division of Cardiology/ JC Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX
*Purpose: Cytomegalovirus (CMV) infection is associated with the development of cardiac allograft vasculopathy (CAV). CAV is one of the leading causes of death and graft…
2019 American Transplant Congress
The Association of BK Virus Infection and Risk of Subsequent Cytomegalovirus Infection after Renal Transplant
M. R. Jorgenson, J. L. Descourouez, B. Lyu, B. C. Astor, C. M. Saddler, S. Parajuli
University of Wisconsin, Madison, WI
*Purpose: Cytomegalovirus (CMV) and BK polyoma virus are opportunistic infections after renal transplant (RTX) that have negative allograft outcomes. Immunosuppressive reduction is the mainstay of…
2019 American Transplant Congress
Risk Stratification of Cytomegalovirus Seropositive Kidney Transplant Recipients for CMV Infection
M. M. Azar¹, A. Baghban¹, K. Belfield¹, R. Assi², M. Malinis¹
¹Yale University, New Haven, CT, ²University of Pennsylvania, Philadelphia, PA
*Purpose: Current consensus guidelines for CMV prevention recommend valganciclovir (VGCV) prophylaxis for 3 months after transplantation for CMV R+ kidney transplant recipients (KTR). This standard…
2019 American Transplant Congress
The Use Of First-year Intravascular Ultrasound In The Tacrolimus Era In Heart Transplantation
S. Dimbil¹, M. Kittleson¹, J. Patel¹, D. Geft¹, R. Cheng¹, R. Levine¹, T. Sato¹, L. Czer¹, R. Zabner², P. Zakowski², J. A. Kobashigawa¹, B. Azarbal¹
¹Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, ²Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Cytomegalovirus (CMV) has been documented as a risk factor for the development of cardiac allograft vasculopathy (CAV) after heart transplantation (HTx). It has not…
2019 American Transplant Congress
Synergistic Effect of HLA Eplet Mismatch Load and CMV Viremia on Clinical Antibody-Mediated Rejection in Lung Transplantation
Y. Im¹, S. Yeramaneni², Y. Yim³, J. Dodderer⁴, M. Askar¹, H. J. Huang⁵
¹Baylor University Medical Center, Dallas, TX, ²Baylor Scott & White Health, Dallas, TX, ³Ross University School of Medicine, Portsmouth, Dominica, ⁴Texas Tech University Health Sciences Center, El Paso, TX, ⁵Houston Methodist Hospital, Houston, TX
*Purpose: De novo donor specific antibodies (dnDSA) occur in up to 50% of lung transplant (LUTX) recipients within one year and are associated with increased…
2019 American Transplant Congress
Using a Commercially Available Assay That Measures Cytomegalovirus-Specific CD4+ and CD8+ T-cell Immunity to Predict Clinically Significant Cytomegalovirus Events in Solid Organ Transplant Recipients
R. Rogers¹, K. Saharia², A. Chandorkar², Z. Weiss³, D. Farmakiotis¹
¹Infectious Diseases, Brown University, Providence, RI, ²Infectious Diseases, University of Maryland, Baltimore, MD, ³Internal Medicine, Brown University, Providence, RI
*Purpose: To assess the diagnostic performance and clinical utility of the Viracor CMV T-cell Immunity Panel (CMV-TCIP), which measures both CMV-specific Cd4+ and Cd8+ T-cell…
2019 American Transplant Congress
Comparing the Rate of Opportunistic Infection after Renal Transplant between Alemtuzumab and Basiliximab for Induction Immunosuppression
J. A. Seaman¹, S. G. Westphal², F. Qiu³, D. Bremers⁴, D. Florescu⁵
¹College of Medicine, University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Nephrology, University of Nebraska Medical Center, Omaha, NE, ³Biostatistics, University of Nebraska Medical Center, Omaha, NE, ⁴Donate Life, Nebraska Medicine, Omaha, NE, ⁵Internal Medicine Division of Infectious Disease, University of Nebraska Medical Center, Omaha, NE
*Purpose: The aim of our study was to compare the outcomes one-year after renal transplant with a focus on opportunistic infections in patients who received…